Glycopyrronium
| Evidence Level: L4 | Predicted Indications: 10 |
Table of Contents
- Glycopyrronium
- Glycopyrronium: From Anticholinergic (Antimuscarinic) Use to Irritable Bowel Syndrome
Glycopyrronium: From Anticholinergic (Antimuscarinic) Use to Irritable Bowel Syndrome
One-Sentence Summary
Glycopyrronium is an anticholinergic (antimuscarinic) agent; its original approved indication is not recorded in this dataset (no EU marketing authorization currently on file). The TxGNN model predicts it may be effective for Irritable Bowel Syndrome, but this direction is currently supported by 0 clinical trials and only 1 tangentially related publication.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available in dataset (drug class: anticholinergic/antimuscarinic agent) |
| Predicted New Indication | Irritable Bowel Syndrome |
| TxGNN Prediction Score | 98.84% |
| Evidence Level | L4 |
| EU Market Status | Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available for glycopyrronium in this dataset (flagged as a High-severity data gap). Based on the information present in the evidence pack, glycopyrronium is a quaternary ammonium antimuscarinic (anticholinergic) compound that acts as a muscarinic (M-) receptor antagonist — a class effect referenced repeatedly across the candidate indications in this pack (e.g., its known use as an inhaled long-acting anticholinergic bronchodilator in COPD).
The mechanistic rationale for irritable bowel syndrome (IBS) is that antimuscarinic drugs can relax intestinal smooth muscle and reduce spasm-related abdominal pain, a mechanism already used therapeutically by other antispasmodics in the same pharmacological class (e.g., hyoscine butylbromide). This is a plausible, class-based rationale rather than drug-specific evidence.
However, the single retrieved literature reference does not study glycopyrronium at all — it examines tricyclic antidepressants’ effects on colonic mechanosensitive nerve fibers in rats. It shares only the general “visceral pain/GI motility” theme with IBS, not a direct pharmacological link to glycopyrronium. No clinical trials of glycopyrronium in IBS exist. The prediction should therefore be read as a class-level hypothesis generated by TxGNN, not as an evidence-backed signal.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 9696463 | 1998 | Preclinical/Animal Physiology | Pain | Studied effects of tricyclic antidepressants (imipramine, desipramine, clomipramine) — not glycopyrronium — on mechanosensitive pelvic nerve afferents innervating the rat colon; relevance to glycopyrronium in IBS is indirect (shared visceral-pain theme only) |
EU Market Information
No EU marketing authorizations found for glycopyrronium in the current dataset (0 authorizations on record).
Safety Considerations
Please refer to the SmPC for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The top-ranked prediction (IBS) rests on evidence level L4 — a class-based mechanistic rationale with a single, drug-nonspecific preclinical paper and zero clinical trials. Combined with the absence of any EU marketing authorization for glycopyrronium in this dataset and a Blocking-severity gap in label safety data, there is not enough evidence to move past a research hypothesis at this time.
To proceed, the following is needed:
- TFDA/EMA product label (SmPC) warnings and contraindications (currently a Blocking data gap)
- Confirmed mechanism of action via DrugBank API (currently a High-severity data gap)
- Drug-specific preclinical or clinical evidence directly evaluating glycopyrronium in IBS, rather than class-effect inference
- Clarification of glycopyrronium’s current EU regulatory/marketing status, since 0 authorizations were found in this dataset
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.